Volume surge · DXCM · Healthcare

DexCom Inc (DXCM) draws heavier trading as weekly gain hits 16.6%

The continuous glucose monitoring maker’s 12-week advance now stands at 37.7%, with trend and relative-strength readings still constructive.

DexCom Inc
Latest83.45 USD
1W move16.6%
Volume1.2x
TrendActive
DexCom glucose monitoring devices beside a market data screen with generic financial charts.

Market update

What happened

DexCom Inc (DXCM) closed at 83.45 USD for the week ended July 31, rising 16.6% on the week and 17.1% over four weeks as trading activity picked up on the active-mover screen.

The confirming evidence is positive, but not one-sided. The trend signal is active, Market Dynamics shows confirmation at 0.84, and Relative Strength is 10.5, while the weekly price path over 52 weeks frames the move as part of a broader recovery rather than live intraday action.

Continue your research

Explore DXCM across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.Insider transactionsSee reported purchases and sales by company directors and executives.

DXCM coverage

Evidence context